Synonyms: example 53 [US11530206]
Compound class:
Synthetic organic
Comment: The chemical structure for inlexisertib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a serine/ threonine kinase inhibitor with antineoplastic potential. The structure is claimed in Deciphera Pharmaceuticals' patent US11530206 in which inhibition of ULK1 kinase is demonstrated [1]. We guess that inlexisertib might be Deciphera's clinical lead ULK inhibitor DCC-3116.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
If inlexisertib is DCC-3116, this lead has progressed to clinical evaluation to determine efficacy in the treatment of selected advanced solid tumours |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04892017 | A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors | Phase 1/Phase 2 Interventional | Deciphera Pharmaceuticals LLC | ||
NCT05957367 | A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Phase 1/Phase 2 Interventional | Deciphera Pharmaceuticals LLC |